Christine M. Hartford, MD
Christine M. Hartford, MD

Christine M. Hartford, MD

Assistant Member, St. Jude Faculty

  • Outpatient Clinical Director, Bone Marrow Transplantation and Cellular Therapy Department



BA – University of Chicago, Chicago, IL
MD – University of Illinois at Chicago
Pediatric Residency – Brown University, Providence, RI
Pediatric Hematology-Oncology Fellowship – St. Jude Children’s Research Hospital, Memphis, TN
Clinical Pharmacology and Pharmacogenomics Fellowship – University of Chicago, Chicago, IL

Research Interests

  • Clinical pharmacology and pharmacogenomics
  • Late effects of stem cell transplantation

Selected Publications

Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.Pharmacogenomics Sep;14(12):1449-66, 2013.

Rujkijyanont P, Morris C, Kang G, Gan K, Hartford C, Triplett B, Dallas M, Srinivasan A, Shook D, Pillai A, Pui CH, Leung W. Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia. Blood Cancer J Aug 30;3:e137, 2013.

Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood May 23;121(21):4366-76, 2013.

Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J, Ware R, Leung W. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant May;19(5):820-30, 2013.

Shook DR, Triplett BM, Srinivasan A, Hartford C, Dallas MH, Pillai A, Laver J, Leung W. Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors. Biol Blood Marrow Transplant Feb;19(2):291-7, 2013.

Inaba H, Yang J, Kaste SC, Hartford CM, Motosue MS, Chemaitilly W, Triplett BM, Shook DR, Pui CH, Leung W. Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol30(32):3991-7, 2012.

Srinivasan A, Flynn P, Gu Z, Hartford C, Lovins R, Sunkara A, Srivastava DK, Leung W, Hayden RT. Detection of respiratory viruses in asymptomatic children undergoing allogeneic hematopoietic cell transplantation. Pediatr Blood Cancer 60(1):149-51, 2012. Epub 2012 Sep 14.

Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase 1 studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.Clin Cancer Res 18(17):4785-93, 2012.

Triplett BM, Wang C, Yang J, Dallas M, Hartford C, Howard V, Pillai A, Shook D, Srinivasan A, Laver J, Leung W. Effects of conditioning regimens and T cell depletion in hematopoietic cell transplantation for primary immune deficiency. Biol Blood Marrow Transplant 18(12):1911-20, 2012.

Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.Blood 120(2):468-72, 2012.

Inaba H, Hartford CM, Pei D, Posner MJ, Yang J, Hayden RT, Srinivasan A, Triplett BM, McCullers JA, Pui CH, Leung W. Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic hematopoietic stem cell transplantation. Br J Haematol 156(1):109-17, 2012.

Pillai A, Hartford C, Wang C, Pei D, Yang J, Srinivasan A, Triplett B, Dallas M, Leung W. Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. Pediatr Transplant 15(6):628-34, 2011.

Mitra AK, Crews K, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME,Hartford C, Raimondi S, Campana D, Downing J, Rubnitz J, Ribeiro R, Lamba JK. Genetic variants in NT5C2 are associated with its expression and cytarabine sensitivity in HapMap cell lines and in AML patients. J Pharmacol Exp Ther 339(1):9-23, 2011.

Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Handgretinger R, Laver JH, Pui CH. High success of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 118(2):223-30, 2011.

Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 28(32):4790-4799, 2010.

Inaba H, Yang J, Pan J, Stokes DC, Krasin MJ, Srinivasan A, Hartford CM, Pui CH, Leung W. Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Cancer 116(8):2020-2030, 2010.

Hartford C, Desai A, Janisch L, Karrison T, Rivera V, Berk L, Loewy J, Kindler H, Stadler W, Knowles H, Bedsrosian C, Ratain M. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus (AP23573) an mTOR inhibitor, in patients with advanced malignancies.Clin Cancer Res 15(4):1428-1434, 2009.

Hartford C, Duan S, Delaney S, Mi S, Kistner E, Lamba J, Huang R, Dolan ME. Population specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood113(10):2145-2153, 2009.

Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 7(9):3038-3046, 2008.

Hartford C, Volchenboum SL, Cohn SL. 3+3 not equal to (rolling) 6. J Clin Oncol 26(2):170-171, 2008.

Hartford CM, Dolan ME. Identifying genetic variants that contribute to chemotherapy-Induced cytotoxicity. Pharmacogenomics 8(9):1159-1168, 2007.

Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 82(4):381-388, 2007.

Hartford CM, Yang W, Cheng C, Fan Y, Liu W, Pounds S, Neale G, Raimondi SC, Bogni A, Trevino L, Dolan ME, Pui CH, Relling MV. Genomic scan implicates novel biological pathways in secondary leukemia. Leukemia 21(10):2128-2136, 2007.

Hartford CM, Vasquez E, Schwab M, Edick MJ, Rehg JE, Grosveld G, Pui CH, Evans WE, Relling MV. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 67(10):4965-4972, 2007.

Hartford CM, Wodowski KS, Rao BN, Khoury JD, Neel MD, Daw NC. Osteosarcoma among children aged 5 years or younger: the St. Jude Children’s Research Hospital experience. J Pediatr Hematol Oncol 28(1):43-47, 2006.

Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, LeBeau MM, Smith MT. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94(2):803-807, 1999.

Last update: July 2014